DrMark Lythgoe

Dr Mark P. Lythgoe is an Academic Clinical Fellow in Medical Oncology and Pharmacist. He is currently undertaking a PhD (primary supervisor Dr Jonathan Krell) exploring the cancer microbiome and live oral biotherapeutics as novel anti-cancer agents. Presently he oversees (principal investigator Dr Krell) the Imperial sponsored MICROBIOME trial (NCT03934827) exploring use of a live oral biotherapeutics..

After studying Pharmacy at Aston University, Mark went on to graduate with a duel distinction in Medicine from Kings College London. After completion of junior doctor posts in west London, he is now undertaking specialist academic training in Medical Oncology. He has a range of academic interests including translational clinical trial development, theranostics, precision oncology cancer microbiome modulation as a therapeutic strategy, healthcare policy, improving clinical trial access and meta-research. He is a member of the ECMC JING steering committee, the London Global Cancer Week steering committee and has also been a member of the Joint Formulary Committee for the British National Formulary (BNF) for 10 years.

He received American Society of Cancer Merit Awards in 2021 and 2022, the Sylvia Lawler Prize on two occasions and has authored >100 peer-reviewed articles including The Lancet, The Lancet Oncology, the BMJ, JAMA Oncology, Nature Reviews Clinical Oncology, Journal of Clinical Oncology, and Trends in Pharmacological Sciences. He also reviews manuscripts for several journals including the Lancet Oncology, the BMJ, Annals of Internal Medicine and NEJM Evidence.

Awards

American Society of Clinical Oncology Merit Award 2021
American Society of Clinical Oncology Genitourinary Cancer Merit Award 2022
Sylvia Lawler Prize (Royal Society of Medicine - Clinical Prize) 2022
Sylvia Lawler Prize (Royal Society of Medicine - Scientific Prize) 2023